GE looks to speed drug discovery with new high capacity system

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/YiuCheung)
(Image: Getty/YiuCheung)
GE has introduced a new high capacity system designed to improve productivity in the increasingly complex drug discovery process.

“The drug discovery process is growing in difficulty and length presenting challenges to leaders of drug discovery programs,”​ said Christina Burtsoff-Asp, GE Healthcare Life Sciences global product marketing manager for label-free technologies.

“With escalating cost pressures and increasingly complex disease targets, improving productivity in early drug discovery has been a challenge,” ​she told us.

In response, GE Healthcare Life Sciences has launched the Biacore 8K+, which, with up to 12 microplates, provides eight times higher throughput than a single-needle system, explained Burtsoff-Asp.

According to the company, the new system can automate more than 4,500 drug candidate/disease target binding experiments in a single run. Burtsoff-Asp said the system also can be paired with GE’s Biacore Insight Evaluation Software to evaluate screening and characterization data.

“The use of SPR as a bio-analytical tool has expanded in recent years to cover process optimization and quality control applications as well as early stage drug discovery,”​ said Burtsoff-Asp.

“SPR can support reliable analysis of critical quality attributes and is considered a novel analytical tool for drug product comparability testing.”

Related news

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more